Pierre S. Sayad
Chief Medical OfficerDr. Pierre S. Sayad, PhD, MS, was Chief Executive Officer of mQOL Data Inc. He serves as Chief Medical Officer of Fennec Pharmaceuticals Inc. from October 28, 2024. Dr. Sayad served as chief operating officer and interim chief medical officer at Zephyr Labz. He serves as Vice President of Global Medical and Scientific Affairs at Karyopharm Therapeutics Inc. Dr. Sayad joined Karyopharm in 2018 and is responsible for overseeing the Karyopharm Therapeutics's Medical Affairs organization, including Scientific Communication, Medical Information and the U.S. and European Medical Science Liaisons (MSLs) teams. Dr. Sayad began his career at Eli Lilly and Company within the commercial organization and helped drive the successful launches of the neuroscience blockbusters Zyprexa®, Cymbalta® and Strattera®. He then joined the strategic management consulting firm Campbell Alliance(a specialized consulting firm focused in the biotech and pharmaceutical industries) and worked across multiple practice areas, with a strong focus in Medical Affairs and led engagements for numerous biotech clients. Joining Onyx Pharmaceuticals in 2011, Dr. Sayad led the Medical Strategy and Operations team and supported the scientific development and subsequent approval and launch of Kyprolis® for relapsed refractory multiple myeloma. Just prior to joining Karyopharm, Dr. Sayad led the global medical affairs and business development organizations at the International Myeloma Foundation (IMF) as SVP, business development, Global Medical Affairs and Strategic Partnerships. Dr. Sayad is an accomplished biopharmaceutical executive with proven success building and leading world-class organizations. During his tenure in the industry, Dr. Sayad has launched nine novel drugs across many therapeutic areas, including oncology (both solid tumors and hematologic malignancies) and neuroscience (depression, schizophrenia, bipolar, ADHD). Trained as a molecular physiologist, Pierre has been heavily involved in the successful commercial launches of several drugs, including oncology drugs at Onyx Pharmaceuticals, Karyopharm Therapeutics, Oncopeptides and CTI Biopharma with Kyprolis, Xpovio, Pepaxto and Vonjo, respectively and Eli Lilly and Company’s blockbuster neuroscience drugs Zyprexa, Cymbalta, Strattera. Dr. Sayad earned his undergraduate degrees from San Jose State University and holds Bachelor of Science degrees in Molecular Physiology and Psychology and a Bachelor of Arts in Music. He completed his graduate work at the School of Medicine, Loma Linda University achieving Master of Science degrees in Molecular Physiology and BioMedical Sciences. Dr. Sayad completed his graduate work in the field of multiple myeloma and holds a Doctor of Philosophy in Psychoneuroimmunology (PNI).
Positions
- Company NameFennec Pharmaceuticals Inc.Stock CodeFENCPositionChief Medical OfficerColleagues
- JSJeffrey S. HackmanCEO & Director
- KIKhalid IslamIndependent Chairman of the Board
- RCRobert C. AndradeChief Financial Officer
- TETerry EvansChief Commercial Officer
- CCChristiana CioffiChief Strategy Officer
- CAChris A. RallisIndependent Director
- MMMarco Maria BrugheraIndependent Director
- JAJodi Ann CookIndependent Director
